The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy

from Oncology Learning Network · host HMP Global

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.

Episode metadata supplied by the publisher feed · Published Dec 12, 2019

Embed this episode

Attribution link and audio player

Ready to play

The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy

0:00 1:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 1 minute long.

When was this Oncology Learning Network episode published?

This episode was published on December 12, 2019.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!